Functionalized gold nanoparticles improve afatinib delivery into cancer cells

Bibliography

• Dreaden EC, Austin LA, Mackey MA, El-Sayed MA. Size matters: gold nanoparticles in targeted cancer drug delivery. Ther Deliv 2012;3(4):457-78
   PubMedGoogle Scholar
• Jain PK, El-Sayed IH, El-Sayed MA. Au nanoparticles target cancer. Nano Today 2007;2(1):18-29
   Web of Science ®Google Scholar
• Xiao Z, Levy-Nissenbaum E, Alexis F, et al. Engineering of Targeted Nanoparticles for Cancer Therapy Using Internalizing Aptamers Isolated by Cell-Uptake Selection. ACS Nano 2012;6(1):696-704
   PubMed Web of Science ®Google Scholar
• Unfried K, Albrecht C, Klotz L-O, et al. Cellular responses to nanoparticles: Target structures and mechanisms. Nanotoxicology 2007;1(1):52-71
   Web of Science ®Google Scholar
• Kim JA, Aberg C, Salvati A, Dawson KA. Role of cell cycle on the cellular uptake and dilution of nanoparticles in a cell population. Nat Nano 2012;7(1):62-8
   Web of Science ®Google Scholar
• Nichols J, Bae Y. Nanotechnology for cancer treatment: possibilities and limitations. In: Bae YH, Mrsny RJ, Park K, editors. Cancer targeted drug delivery. Springer; New York: 2013. p. 37-56
   Google Scholar
• Dykman LA, Khlebtsov NG. Uptake of engineered gold nanoparticles into mammalian cells. Chem Rev 2014;114(2):1258-88
   PubMed Web of Science ®Google Scholar
• Jain S, Hirst DG, O’Sullivan JM. Gold nanoparticles as novel agents for cancer therapy. Br J Radiol 2012;85(1010):101-13
   PubMed Web of Science ®Google Scholar
• Coelho SC, Rocha S, Juzenas P, et al. Gold nanoparticle delivery-enhanced proteasome inhibitor effect in adenocarcinoma cells. Expert Opin Drug Deliv 2013;10(10):1345-52
   PubMed Web of Science ®Google Scholar
• Han G, Ghosh P, Rotello VM. Functionalized gold nanoparticles for drug delivery. Nanomedicine (Lond) 2007;2(1):113-23
   PubMed Web of Science ®Google Scholar
• Rosi NL, Giljohann DA, Thaxton CS, et al. Oligonucleotide-modified gold nanoparticles for intracellular gene regulation. Science 2006;312(5776):1027-30
   PubMed Web of Science ®Google Scholar
• Comenge J, Sotelo C, Romero F, et al. Detoxifying antitumoral drugs via nanoconjugation: the case of gold nanoparticles and cisplatin. PLoS ONE 2012;7(10):e47562
   PubMed Web of Science ®Google Scholar
• Kao HW, Lin YY, Chen CC, et al. Biological characterization of cetuximab-conjugated gold nanoparticles in a tumor animal model. Nanotechnology 2014;25(29):295102
   PubMed Web of Science ®Google Scholar
• Li J, Gupta S, Li C. Research perspectives: gold nanoparticles in cancer theranostics. Quant Imaging in Med Surg 2013;3(6):284-91
   PubMedGoogle Scholar
• Coelho SC, Rocha S, Pereira MC, et al. Enhancing proteasome-inhibitor effect by functionalized gold nanoparticles. J Biomed Nanotechnol 2014;10(4):717-23
   PubMed Web of Science ®Google Scholar
• Bartczak D, Kanaras AG. Preparation of peptide-functionalized gold nanoparticles using one Pot EDC/Sulfo-NHS coupling. Langmuir 2011;27(16):10119-23
   PubMed Web of Science ®Google Scholar
• Tsai DH, Davila-Morris M, DelRio FW, et al. Quantitative determination of competitive molecular adsorption on gold nanoparticles using attenuated total reflectance-Fourier transform infrared spectroscopy. Langmuir 2011;27(15):9302-13
   PubMed Web of Science ®Google Scholar
• Qian Y, Qiu M, Wu Q, et al. Enhanced cytotoxic activity of cetuximab in EGFR-positive lung cancer by conjugating with gold nanoparticles. Sci Rep 2014;4:7490
   PubMed Web of Science ®Google Scholar
• Shukla R, Bansal V, Chaudhary M, et al. Biocompatibility of gold nanoparticles and their endocytotic fate inside the cellular compartment: a microscopic overview. Langmuir 2005;21(23):10644-54
   PubMed Web of Science ®Google Scholar
• Connor EE, Mwamuka J, Gole A, et al. Gold nanoparticles are taken up by human cells but do not cause acute cytotoxicity. Small 2005;1(3):325-7
   PubMed Web of Science ®Google Scholar
• Ali MRK, Panikkanvalappil SR, El-Sayed MA. Enhancing the efficiency of gold nanoparticles treatment of cancer by increasing their rate of endocytosis and cell accumulation using rifampicin. J Am Chem Soc 2014;136(12):4464-7
   PubMed Web of Science ®Google Scholar
• Chithrani BD, Ghazani AA, Chan WC. Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. Nano Lett 2006;6(4):662-8
   PubMed Web of Science ®Google Scholar
• Pelgrift RY, Friedman AJ. Nanotechnology as a therapeutic tool to combat microbial resistance. Ad Drug Deliv Rev 2013;65(13–14):1803-15
   PubMed Web of Science ®Google Scholar
• Ioannou N, Dalgleish AG, Seddon AM, et al. Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells. Br J Cancer 2011;105(10):1554-62
   PubMed Web of Science ®Google Scholar
• Tsai YC, Yeh CH, Tzen KY, et al. Targeting epidermal growth factor receptor/human epidermal growth factor receptor 2 signalling pathway by a dual receptor tyrosine kinase inhibitor afatinib for radiosensitisation in murine bladder carcinoma. Eur J Cancer 2013;49(6):1458-66
   PubMed Web of Science ®Google Scholar
• Awada AH, Dumez H, Hendlisz A, et al. Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors. Invest New Drugs 2013;31(3):734-41
   PubMed Web of Science ®Google Scholar
• Li D, Ambrogio L, Shimamura T, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008;27(34):4702-11
   PubMed Web of Science ®Google Scholar
• D’Arcangelo M, Hirsch FR. Clinical and comparative utility of afatinib in non-small cell lung cancer. Biologics 2014;8:183-92
   PubMedGoogle Scholar
• Yang JC-H, Wu Y-L, Schuler M, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol 2015;16(2):141-51
   PubMed Web of Science ®Google Scholar
• Li D, Ambrogio L, Shimamura T, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008;27(34):4702-11
   PubMed Web of Science ®Google Scholar
• Chen X, Zhu Q, Zhu L, et al. Clinical perspective of afatinib in non-small cell lung cancer. Lung cancer 2013;81(2):155-61
   PubMed Web of Science ®Google Scholar
• Guan SS, Chang J, Cheng CC, et al. Afatinib and its encapsulated polymeric micelles inhibits HER2-overexpressed colorectal tumor cell growth in vitro and in vivo. Oncotarget 2014;5(13):4868-80
   PubMed Web of Science ®Google Scholar
• Turkevich J, Stevenson PC, Hillier J. A study of the nucleation and growth processes in the synthesis of colloidal gold. Discuss Faraday Soc 1951;11:55-75
   Google Scholar
• Kimling J, Maier M, Okenve B, et al. Turkevich method for gold nanoparticle synthesis revisited. J Phys Chem B 2006;110(32):15700-7
   PubMed Web of Science ®Google Scholar
• Hermanson GT. Zero-length crosslinkers. In: Hermanson GT, editor. Bioconjugate Techniques. 2nd edition. Academic Press; New York: 2008. p. 213-33
   Google Scholar
• Baptista P, Doria G, Henriques D, et al. Colorimetric detection of eukaryotic gene expression with DNA-derivatized gold nanoparticles. J Biotechnol 2005;119(2):111-17
   PubMed Web of Science ®Google Scholar
• Hermanson GT. Modification with synthetic polymers. In: Hermanson GT, editor. Bioconjugate Techniques. 2nd edition. Academic Press; New York: 2008. p. 936-60
   Google Scholar
• Frolov A, Schuller K, Tzeng CW, et al. ErbB3 expression and dimerization with EGFR influence pancreatic cancer cell sensitivity to erlotinib. Cancer Biol Ther 2007;6(4):548-54
   PubMed Web of Science ®Google Scholar
• Nakamura H, Takamori S, Fujii T, et al. Cooperative cell-growth inhibition by combination treatment with ZD1839 (Iressa) and trastuzumab (Herceptin) in non-small-cell lung cancer. Cancer Lett 2005;230(1):33-46
   PubMed Web of Science ®Google Scholar